Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma

NCT00338130 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00338130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00338130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2006
Completion date
July 31, 2013
Enrollment
239 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma